To our knowledge, this is the first study to assess the relationship between expression of p52, a major component of the non-canonical NF-κB pathway, and epithelial ovarian cancer prognosis, particularly high-grade serous ovarian cancer. The gene discussed is NFKB2; the disease is ovarian serous adenocarcinoma.